SCHEMBL12500709

SCHEMBL12500709

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(S(F)(F)(F)(F)F)ccc3Cl)cc2)ccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 13/20 0.67
KDR P35968 6/20 0.67
EPHX2 P34913 4/20 0.67
RET P07949 4/20 0.67
MAPK14 Q16539 4/20 0.67
BRAF P15056 4/20 0.67
ABL1 P00519 3/20 0.67
EPHA2 P29317 3/20 0.67
MAP3K20 Q9NYL2 3/20 0.67
AURKB Q96GD4 3/20 0.67
RIPK2 O43353 2/20 0.67
ABCB11 O95342 2/20 0.67
HTR1A P08908 2/20 0.67
PDGFRB P09619 2/20 0.67
ADORA3 P0DMS8 2/20 0.67
KIT P10721 2/20 0.67
FGFR1 P11362 2/20 0.67
PDGFRA P16234 2/20 0.67
FLT1 P17948 2/20 0.67
MAOA P21397 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12500712 0.90 MAPK14 (0.67) RAF1KDREPHX2RETMAPK14
SCHEMBL12500767 0.89 RAF1 (0.73) RAF1KDREPHX2RETMAPK14
SCHEMBL1660281 0.88 RAF1 (0.69) RAF1KDREPHX2RETMAPK14
SCHEMBL1660185 0.86 RAF1 (0.67) RAF1KDREPHX2RETMAPK14
SCHEMBL12500806 0.86 RAF1 (0.73) RAF1KDREPHX2RETMAPK14
SCHEMBL1660255 0.85 RAF1 (0.79) RAF1KDREPHX2RETMAPK14
SCHEMBL15367107 0.85 RAF1 (0.68) RAF1KDREPHX2RETMAPK14
SCHEMBL15366992 0.85 KDR (0.72) RAF1KDREPHX2RETMAPK14
SCHEMBL16621444 0.84 RAF1 (0.68) RAF1KDREPHX2RETMAPK14
SCHEMBL257980 0.83 RAF1 (0.82) RAF1KDREPHX2RETMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937088-B2 Ureas for the treatment and prevention of cancer ASTAR BIOTECH LLC (US) 2015-01-20 US claimed
EP-2661434-A1 NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER Beta Pharma Canada Inc. (CA) 2013-11-13 EP claimed
US-20130296380-A1 Novel Ureas for the Treatment and Prevention of Cancer BETA PHARMA CANADA INC. (CA) 2013-11-07 US claimed
WO-2012094451-A1 NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER BETA PHARMA CANADA INC. (CA) 2012-07-12 WO claimed
US-8937088-B2 Ureas for the treatment and prevention of cancer ASTAR BIOTECH LLC (US) 2015-01-20 US disclosed
EP-2661434-A1 NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER Beta Pharma Canada Inc. (CA) 2013-11-13 EP disclosed
US-20130296380-A1 Novel Ureas for the Treatment and Prevention of Cancer BETA PHARMA CANADA INC. (CA) 2013-11-07 US disclosed
WO-2012094451-A1 NOVEL UREAS FOR THE TREATMENT AND PREVENTION OF CANCER BETA PHARMA CANADA INC. (CA) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296380-A1 Novel Ureas for the Treatment and Prevention of Cancer FLT1, FLT4, KIT RAF1 7/4885KDR 5/4885EPHX2 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.